Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.
about
Respiratory viruses from hospitalized children with severe pneumonia in the Philippines.Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease.Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccineThe respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodentsAssembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Respiratory syncytial virus represses glucocorticoid receptor-mediated gene activation.Therapeutic targeting of respiratory syncytial virus G-protein.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F proteinRespiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trialsAntibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.Relative impact of influenza and respiratory syncytial virus in young childrenCotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein.Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomainsA nonviral pHEMA+chitosan nanosphere-mediated high-efficiency gene delivery systemIntranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice.Primary high-dose murine norovirus 1 infection fails to protect from secondary challenge with homologous virusRecent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus.Respiratory syncytial virus disease: update on treatment and prevention.Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention.The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection.Direct whole-genome deep-sequencing of human respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- and intra-host evolution.Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogensIntranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus.The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV.The NS1 protein of Respiratory syncytial virus blocks glucocorticoid receptor nuclear translocation by targeting IPO13 may account for glucocorticoid insensitive.Respiratory syncytial virus infection in children with severe motor and intellectual disabilities.
P2860
Q30529666-B701D33B-C31A-44D6-BB2F-4487201B0071Q33558356-C39EE3D0-9D85-4180-8111-30712D3A0158Q33840252-F036653B-0A49-482E-AB56-02C573770B08Q34059404-62C277C5-0932-4F29-B2CD-5198A7CDB611Q34170117-7E0729BB-2047-4FE1-8D82-3A6ED81968A5Q34222406-47EAAC1F-55E4-410D-8C34-E2C9F0FF73D3Q34457791-3D5C2674-1FEC-4ED1-A3DE-500318B60193Q34566553-C6D1E7E4-324E-4CD8-8297-2F5DE5A9D3D3Q34603346-41C02A77-8C5E-475F-9353-EA26FFCD0A25Q34990420-10E3133B-3908-4638-9C02-08FA7C1F719FQ35077892-8325314F-0E94-49CB-8676-18194F3FEEB5Q35745343-860F0419-777F-4001-A742-83A92AC9C9BFQ35761061-9B66175D-7FE4-411E-AE02-7FD54D4FFC51Q36005114-F0537D79-ECDB-46C2-AED2-91E66A8521A9Q36030806-9942CE20-70E6-45BD-B968-B5BD0949428DQ36256989-6B1AAC9E-D820-4D17-8B3A-8D5530DE3788Q36363325-18B1AC70-0AA3-4EF1-954C-8BB828347365Q36776952-C37CE556-9345-4A76-AD51-EE9855F0D3BFQ36937656-2E78BF24-2A5B-47E6-87E6-D2E5A033D208Q36994716-336E5C32-2D64-4714-9AE1-F28DBD1F2D29Q37086092-882C0B74-9092-4381-B6FA-52A1EC72284DQ37232803-AC45EBA7-737C-47DD-967A-00DFE6636948Q37412509-AB380572-7A4F-4417-BDA9-21960C424921Q37822453-55AF7E0B-5404-430B-A10C-371408358C8AQ37841269-5B71DCD2-68F5-4D08-AE2A-53965B57B882Q38696909-5CCC14FB-EAA5-42F0-BA93-B11504C08B4EQ39398265-0D6681AC-C8C8-4A00-92B9-8EBBE29AC38AQ39780308-E473EB9D-C26E-4EFE-8C44-9E94A71AC6E5Q40076730-33358FC5-34DA-4380-B1AC-14F2E317277BQ40163890-EDCC219F-F8F2-45AE-B97A-6667144AA8EDQ41926470-BFAA19BB-BDDF-46D3-A87E-1C69A2194EB5Q45145012-AAF3569C-89FA-4694-9FDA-1B41B5402971
P2860
Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.
@en
type
label
Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.
@en
prefLabel
Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.
@en
P1476
Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward
@en
P2093
Ultan F Power
P356
10.1016/J.JCV.2007.10.024
P577
2008-01-01T00:00:00Z